WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Grace Liu
Patent Agent
Patents and Innovations
San Francisco
gliu@wsgr.com

D415-947-2143

Download vCard
Open PDF

Grace Liu is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her work focuses on patent preparation and prosecution in the fields of biotechnology, genomics, protein engineering, bioinformatics, and machine learning.

Prior to joining the firm, Grace obtained an M.S. in biomedical informatics at Harvard Medical School for her work with the Dr. David Liu lab developing bioinformatics algorithms to characterize genomic changes in immunotherapy-resistant tumor samples. As an undergraduate, she worked in the Dr. Frances Arnold lab to develop machine learning models for predicting protein function and interactions.

Experience

Grace Liu is a patent agent in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations group. Her work focuses on patent preparation and prosecution in the fields of biotechnology, genomics, protein engineering, bioinformatics, and machine learning.

Prior to joining the firm, Grace obtained an M.S. in biomedical informatics at Harvard Medical School for her work with the Dr. David Liu lab developing bioinformatics algorithms to characterize genomic changes in immunotherapy-resistant tumor samples. As an undergraduate, she worked in the Dr. Frances Arnold lab to develop machine learning models for predicting protein function and interactions.

Education
  • M.S., Biomedical Informatics, Harvard University, 2024
  • B.S., Biology, California Institute of Technology, 2023
Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • M.S., Biomedical Informatics, Harvard University, 2024
  • B.S., Biology, California Institute of Technology, 2023
Admissions
  • U.S. Patent and Trademark Office

Select Publications

    • Co-author, “A combinatorially complete epistatic fitness landscape in an enzyme active site,” PNAS, 2024
    • Co-author, “Experience-dependent plasticity in an innate social behavior is mediated by hypothalamic LTP,” PNAS, 2020
Insights

Select Publications

    • Co-author, “A combinatorially complete epistatic fitness landscape in an enzyme active site,” PNAS, 2024
    • Co-author, “Experience-dependent plasticity in an innate social behavior is mediated by hypothalamic LTP,” PNAS, 2020

Biological Sciences and Biotechnology

  • Cancer biology
  • Genetics
  • Genomics
  • Immuno-oncology
  • Molecular genetics
  • Proteomics

Therapeutics and Drug Discovery

  • Gene editing
  • Gene therapy
  • Immunotherapy targets

Diagnostics and Medical Devices

  • Bioinformatic
  • Biomedical engineering
  • Diagnostics
  • Digital pathology

Chemistry and Material Science

  • Chemoenzymatic synthesis
  • Protein engineering
  • Protein folding

Engineering and Technology

  • AI
  • Computer science
  • Machine learning

Genomics and Data Analysis

  • Bioinformatics algorithms
  • Computational biology
  • Next-generation sequencing
  • Sequencing
  • Single-cell sequencing

Miscellaneous

  • Cancer
  • Physiology
Technical Fluency

Biological Sciences and Biotechnology

  • Cancer biology
  • Genetics
  • Genomics
  • Immuno-oncology
  • Molecular genetics
  • Proteomics

Therapeutics and Drug Discovery

  • Gene editing
  • Gene therapy
  • Immunotherapy targets

Diagnostics and Medical Devices

  • Bioinformatic
  • Biomedical engineering
  • Diagnostics
  • Digital pathology

Chemistry and Material Science

  • Chemoenzymatic synthesis
  • Protein engineering
  • Protein folding

Engineering and Technology

  • AI
  • Computer science
  • Machine learning

Genomics and Data Analysis

  • Bioinformatics algorithms
  • Computational biology
  • Next-generation sequencing
  • Sequencing
  • Single-cell sequencing

Miscellaneous

  • Cancer
  • Physiology
Focus Areas
  • Artificial Intelligence and Machine Learning
  • Biotech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Life Sciences
  • Patents and Innovations
  • Software
Recent Insights
Client Highlights
Wilson Sonsini Advises Freenome on IP Matters Related to Business Combination, Public Company Launch
On July 20, 2026, Freenome Holdings, Inc. (Freenome), an early cancer detection company developing blood-based screening tests, announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (PCSC). The combined company is renamed Freenome, Inc., and its common stock commenced trading on the Nasdaq Capital Market on July 21, 2026, under the new ticker symbol “FRNM.” Wilson Sonsini Goodrich & Rosati advised Freenome on IP matters related to the transaction.

Freenome's Personalized Cancer Detection (PCD) approach to screening combines multiomic blood-based tests with integrated digital solutions to help providers identify eligible patients and deliver guideline-based screening for each individual based on their health profile. The company will use the proceeds from this transaction to support its mission of making early cancer detection simple, accessible, and personalized. 

The Wilson Sonsini team that advised Freenome on IP matters related to the transaction included Ali Alemozafar, Dawson Wong, Matthew Garnica, and Grace Liu.

For more information, please see Freenome’s news release.
Learn More
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.